Illumina, Inc. (NASDAQ:ILMN), a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, today sent a third letter to its stockholders highlighting Illumina’s tremendous growth prospects in the next generation sequencing market. The letter urges stockholders to reject Roche’s efforts to acquire Illumina at a grossly inadequate price, and reiterates the Board’s recommendation to vote for the election of Illumina’s highly qualified director nominees at its 2012 Annual Meeting of Stockholders and against Roche’s other proposals by completing the WHITE proxy card today. Included below is the full text of the letter to Illumina stockholders: April 3, 2012 Dear Fellow Stockholder: ACT NOW TO PROTECT THE VALUE OF YOUR INVESTMENT IN ILLUMINA VOTE THE WHITE PROXY CARD TODAY!
|“Illumina is like the Apple of the genomics business. Tools made by the San Diego company are revered by genomics researchers around the world just like millions of consumers love their iPhones and iPads. And Illumina holds its dominant position at an enviable moment in history, as we’re heading into a scientific golden age when human genomes will be sequenced for $1,000 or less.” – Xconomy reporter Luke Timmerman, March 6, 2012|
|“… the potential for sequencing in the clinical markets is large (billions of dollars or more), and the cost of sequencing is approaching a point where it is rapidly becoming economical for clinical trials and cancer management.” – J.P. Morgan Securities LLC analyst Tycho W. Peterson, January 25, 2012|
Your Board is unanimous in its conviction that execution of our strategic plan will create considerably more value than Roche is offering. We will not let Roche capture value at the expense of Illumina’s stockholders.ILLUMINA’S BOARD WILL PROTECT YOUR INVESTMENT AND HELP YOU ACHIEVE MAXIMUM VALUE FOR YOUR SHARES We are seeking your support to re-elect to Illumina’s Board four highly qualified and experienced directors – A. Blaine Bowman; Karin Eastham; Jay T. Flatley, President and CEO; and William H. Rastetter, Chairman – all of whom are committed to and focused on protecting your best interests. The current Board, if re-elected, will not allow Roche to succeed in its opportunistic attempt to rob Illumina stockholders of the tremendous value creation opportunities that lay ahead. YOUR VOTE IS IMPORTANT – PLEASE VOTE THE WHITE PROXY CARD TODAY! Whether or not you plan to attend the Annual Meeting, you have the opportunity to protect your investment by promptly voting the WHITE PROXY CARD. We urge you to vote by telephone, by Internet, or by signing, dating and returning the enclosed WHITE PROXY CARD in the postage-paid envelope provided. On behalf of the Board of Directors, we thank you for your continued support.
|William H. Rastetter, Ph.D.||Jay T. Flatley|
|Chairman||President and CEO|
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50226797&lang=en